Why Most People Quit GLP-1s Within a Year — and How to Beat the Odds

Published July 18, 2026

Sit With That Number for a Second

64.8%. Nearly two out of three people who start one of the most effective weight-loss medications ever studied stop taking it within twelve months.

That's not a marketing statistic — it's from Rodriguez and colleagues' retrospective cohort of 125,474 adults published in JAMA Network Open in January 2025, one of the largest real-world GLP-1 adherence datasets assembled. And it sits in strange tension with the trial data everyone quotes: semaglutide produced 14.9% mean weight loss in STEP 1, tirzepatide 20.9% in SURMOUNT-1. The medications work. People stop anyway.

Why? The study found three signals worth taking seriously.

Driver 1: Side Effects — Front-Loaded and Frequently Survivable

Patients who experienced moderate or severe gastrointestinal adverse events had a 19–38% higher hazard of discontinuing. No surprise there; nausea is miserable.

What the discontinuation number hides is the timing. In the trials, GI effects clustered during dose titration — the first weeks at each new dose — and were mostly mild-to-moderate, settling as the body adjusted. A meaningful share of year-one quitters are likely people who hit week three, felt awful, had no one to call, and made a permanent decision about a temporary problem.

This is, bluntly, the case for choosing a provider with an actual care team over the cheapest checkout page. Dose-timing adjustments, food strategies, and sometimes just hearing "this is normal and it fades" are the difference between a rough month and a quit.

Driver 2: Money — the Quiet Adherence Variable

Here's the finding that should get more attention: among patients with diabetes, household income above $80,000 was associated with a 28% lower discontinuation rate. Affordability didn't just affect who started treatment. It shaped who stayed on it.

That reframes the pricing conversation. When treatment runs $499–$1,000+ per month, continuing is a monthly financial decision — and eventually the answer is no. At $86/month, the same decision has a different answer for a lot more households. Sustainable pricing isn't a discount; functionally, it's an adherence intervention.

Driver 3: Early Results — and the Restart Cycle

Every 1% of body weight lost was associated with roughly 3% lower discontinuation hazard. Results keep people on treatment; plateaus and slow starts push people off it.

And then the study's most human finding: among those who quit and later regained weight, many restarted — about one in three without diabetes within a year. Which means a meaningful number of people are cycling: quit, regain, return, repeat. Every cycle costs money, momentum, and morale. The cheaper path, in every sense, is not quitting for solvable reasons in the first place.

What Actually Improves the Odds

The evidence suggests three unglamorous things: pick a monthly price you could pay for two years without flinching; treat titration side effects as a clinical conversation, not a verdict; and judge progress on the trial timeline (68–72 weeks), not a six-week window. Our guide to every GLP-1 access option in 2026 prices the pathways honestly if cost is your binding constraint.

Frequently Asked Questions

What percentage of people stop taking GLP-1s?

In the 2025 JAMA Network Open cohort of 125,474 US adults, 64.8% of patients without type 2 diabetes and 46.5% with diabetes discontinued within one year. By two years, overall discontinuation exceeded 70% in related analyses.

Why do most people quit semaglutide or tirzepatide?

Three factors were most strongly associated: gastrointestinal side effects, lower income, and less early weight loss. Side effects are typically front-loaded during titration; cost is a function of provider and pathway choice.

Does quitting undo the results?

Withdrawal data (STEP 4, JAMA 2021) shows most lost weight returns after stopping. See our full breakdown of what happens when you stop semaglutide.

How does cost affect staying on treatment?

Higher income was significantly associated with lower discontinuation in the JAMA cohort — affordability shapes persistence, not just access. Comparing true all-in monthly cost before starting (see our cost comparison tool) matters more than any single month's price.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Compounded medications are not FDA-approved. Clinical trial results describe FDA-approved formulations in study populations and are not guarantees of individual outcomes. Always consult a licensed healthcare provider before starting, changing, or stopping any prescription medication.

Sources

treatment